Objectives: Comparison of the ability to inhibit alloactivated lymphocytes proliferation of human Wharton Jelly (WJ) and amniotic membrane (AM) mesenchymal stem cells (MSCs) from preterm and term pregnancies.
INTRODUCTION
The recent progress in clinical translation of basic stem cell research is based on two main types of human cells: Pluripotent stem cells (embryonic or induced) and mesenchymal stem cells (MSCs). With the advance of science we currently know MSCs have different characteristic depending on the tissue they originate, donor age and culture conditions [1] [2] [3] . Therefore, the key challenge for researchers remain fitting best type of stem cells for specific therapies. MSCs derived from fetal tissues such as Wharton Jelly (WJ-MSCs) and amniotic membrane (AM-MSCs) are very promising for vide spectrum of applications. Numerous data indicate that these early-stage cells exert significantly lower immunogenicity but similar immunomodulatory and neuroprotective potential when compared to cells derived from mature tissues [2, 4] . It was demonstrated, that MSCs isolated from perinatal tissues not only fulfill general characteristics of MSCs [2, 5, 6 ], but present higher proliferative potential and less typical signs of senescence at an early stage in comparison to adult, bone marrow or adipose derived MSCs [2, 7] . Although the mechanism of MSCs therapeutic action is not fully elucidated, there is mounting evidence that paracrine enhancement of endogenous regenerative potential and selective modulation of immune system is predominantly responsible for the vast MSCs effects after transplantation, not as previously thought simple replacement of damaged tissue [8, 9] .
This feature can and should be introduced in prevention and treatment of perinatal brain hemorrhage and acute respiratory syndrome associated with preterm deliveries. The use of autologous MSCs from fetal tissues gives opportunity to prompt start of the therapy, without the burden of matching recipient and the donor. Our previous research has proven that fetal derived MSCs from WJ and AM have different, but promising cytokine profile and both share the capacity to inhibit proliferation of allo-activated lymphocytes in an in vitro transplantation model [2] . It is known that fetal MSCs obtained from fetal tissues from term pregnancies complicated with preeclampsia have similar features when compared with healthy pregnancies [10] . In current research we try to find out if immature tissues obtained from preterm delivery are rich in MSCs with similar immunomodulative properties as ones from term deliveries.
MATERIAL AND METHODS

Amniotic membrane and umbilical cord donation
Ethical approval was received from the Medical University of Warsaw Ethics Committee and informed consent was obtained from all women who donated tissues for the experiment. Amniotic membrane (AM, 10 cm 2 ) and umbilical cord (WJ, 10 cm) samples were taken from 5 healthy pregnant patients undergoing scheduled cesarean section at term of delivery, and one patient who had premature delivery at 29 weeks due to spontaneous contractions. Similar to our previous experiments AM and WJ fragments were placed in sterile containers with PBS + 1% penicillin and streptomycin solution, and transferred to the laboratory unit within 1 to 2 hours. All further stages of isolation and cell culture were performed under a laminar flow hood.
Amniotic membrane
Amnion layer was mechanically separated from the chorion and, after rinsing of blood and debris it was immersed in 70% ethanol solution for 3 seconds to eliminate potential fungal or bacterial contamination. Tissue was washed twice in standard Phosphate Buffered Saline (PBS) and incubated in 0.25% trypsin-EDTA solution (Gibco) for 1 h in 37°C with continuous stirring on roller mixer, washed again in PBS and exposed to 1 mg/mL collagenase type I (Sigma-Aldrich), C0130)/0.025mg/mL DNAse (Sigma-Aldrich) solution. The membrane was incubated in 37°C for 60 to 90 minutes until complete tissue disintegration. The released cells were centrifuged, washed twice, suspended in growth medium (GM) consisting of DMEM-LG (Dulbecco's modified Eagle's Medium with low glucose; Lonza) supplemented with fetal calf serum (FCS; 15%; Lonza) and antibiotic-antimycotic solution (Penicillin-streptomycin-amfoterycin; 1.5%; Invitrogen), and seeded on Ø 100 mm culture dish (BD Primaria TM ). After 48 hours the dishes were washed with PBS to remove non-adherent cells and debris and suspended in GM again. When primary cultures reached subconfluency, cells were detached by short trypsinisation (2 min in 0.25% trypsin with 1mM EDTA; Invitrogen) and replated at a density of 5.0 × 10 3 cells/cm 2 for further growth.
Wharton Jelly
Collected umbilical cord fragments were washed from blood, devascularised and cut with sterile surgical knife into about 3 mm 3 fragments and placed on Ø 100 mm culture dish (BD Primaria TM ) in GM and cultured in 37°C and 5% CO 2 atmosphere. The medium was changed every 2-3 days without touching the explants. After 10 days, the explants were collected, the dishes washed to remove non-adherent cells and debris. The MSCs cells which migrated from the WJ explants were detached from the culture dish and reseeded on a new dish in a density of 5.0 × 10 3 cells/cm 2 for further growth.
All experiments were performed on cells (all types) between passage 3 and 5.
Flow cytometry, differentiation assay, and morphology of acquired cells
The criteria of human MSCs identification established in 2006 by the International Society for Cell Therapy were tested. Both, WJ and AM-derived cells displayed typical MSCs spindle shape morphology and created colonies on plastic surface regardless of fetal tissues maturity. To evaluated the multipotency of isolated MSCs, cells were induced to differentiate into adipocytes, osteocytes and chondrocytes using adequate differentiation media according to manufacturer protocols (Human Mesenchymal Stem Cell Functional Identification Kit; R&D Biosystems, Minneapolis, USA). MSCs osteogenic potential was then confirmed by staining mineral deposits with Alizarin Red solution (Sigma-Aldrich). Lipid droplets accumulated by adipocytes were visualized with Oil Red O solution (Sigma-Aldrich). To prove the induction of chondrogenesis in MSCs, toluidine blue staining was performed, in which cartilaginous extracellular matrix was stained purple (metachromasia). The results of differentiation is shown on Figure 1 . The immunophenotype of MSCs was assessed by flow cytometry, using Human MSCs Analysis Kit (BD Stemflow) for the presence of cell surface antigens CD73, CD90, CD105, and the absence of CD34, CD45, CD11b, CD19 and HLA-DR.
Mixed lymphocytes reaction (MLR)
One of approved methods to confirm MSCs immunosuppressive potential is to assess their capacity to inhibit proliferation of allo-activated lymphocytes in Mixed Lymphocyte Reaction (MLR) [11] . At first peripheral blood mononuclear cells (PBMCs) were isolated from venous blood of healthy blood donors by density gradient centrifugation onto Histopaque-1077 (Sigma Aldrich). Half of the isolated PBMCs from each donor were inactivated by gamma irradiation for 90 min.
MLR aims to measure the proliferation rate of lymphocytes from donor A in the response to lymphocytes from unrelated donor B. To assess activity of lymphocyte from a certain donor, one population was always irradiated (marked as "x"). Therefore, cells were tested in the following combinations: ABx and BAx. The basic proliferation level was measured by control combinations: AAx and BBx To evaluate the in vitro immunosuppressive potential of MSCs, they were added to the mixture of lymphocytes from donors A and B (PBMCs donors were unrelated to MSCs donor). The experiments were performed on a 96-well flat-bottom plates (Greiner). Lymphocytes were seeded in concentration of 1 × 10 5 cells/well per donor and were cultured with or without addition of MSCs (1 × 10 4 /well). PBMCs cultures without MSCs were used as controls. Cells were cultured for 5 days at 37ºC in a humidified atmosphere with 5% CO 2 . After 5 days, the cells were pulsed with 1 μCi/well of 3H-thymidine (113 Ci/nmol, NEN) for the last 18 hours of the incubation and harvested with an automated cell harvester (Skatron). The amount of 3H-thymidine incorporated into the cells was measured using a Wallac Microbeta scintillation counter (Wallac), giving the level of radioactivity as 'Corrected Counts per Minute' (CCPM). Experiments were performed in triplicates.
Statistical method
Statistical analysis was performed in order to evaluate the significance of term MSCs effect on lymphocyte proliferation in MLR. The data distribution was assessed using Shapiro-Wilk test. Due to abnormal distribution and limited size of analyzed groups (n = 10), non-parametric Wilcoxon matched-pairs signed-ranks test was used. A level of significance was set at p < 0.05.
RESULTS
Expression of surface markers in MSCs using flow cytometry analysis
The cluster of differentiation antigens (CD) profiles of cultured cells were rated by flow cytometry after 3-4 passages. It was found that mean expression of CD73, CD90, CD105 surface markers with simultaneous absence of: CD11b, CD14, CD19, CD34, CD45 and HLA-DR was for term AM-MSCs 72.1% (median 87.6%, SD = 0.22). In this population, a mean of 90.6% (median 91.6%, SD = 0.13) has been positive for CD44, an additional MSCs marker. In preterm AM-MSCs samples, the mean values were even better -96.2% and 94.1% respectively. The results for WJ-MSCs was similar and can be seen in Table 1 . Despite the same procedures and conditions, the tempo of culture varied between samples due to ontogenic dfifferences, but in the case of premature AM we were able to harvest 8 million of MSCs after 7 days from the delivery. 
The extend of MLR inhibition does not differ between analyzed MSCs types
The mean inhibition of proliferation rate after addition of premature MSCs to the MLR is similar to MSCs derived at term. To avoid distortion of the results due to individual differences in donor's lymphocytes activity we calculated 'MLR ratio' by dividing the result of allo-stimulation by allo-stimulation with MSCs. Mean MLR ratio for Term-AM-MSCs was 3.12 and for Preterm AM-MSCs 2.90 (median). For WJ-MSCs for term samples mean MLR ratio was 2.43 and for preterm median ratio was 7.82. In statistical evaluation (the Wilcoxon test ), the average decline did not differ significantly between AM-MSCs and WJ-MSCs.
DISCUSSION
Since 1961 when James Till, a biophysicist, and Ernest McCulloch, a haematologist, described their accidental findings which demonstrated the existence of rare cells that can proliferate and rebuild hematopoietic lineages, stem cells research was seeping towards the very centre of scientific world [12] . Later, they defined stem cells as those, with the capacity to both self-renew and differentiate to various adult cells [13] . Researchers had to overcome tremendous obstacles to push knowledge to the point where we stand today. The history of stem cell research is a line of battles waged not only at the laboratory bench, but also on the field of ethics. In 2016 the international guidelines for development of research and the clinical application of stem cell science has been finally accepted [14] . The recent advance in clinical translation of basic stem cell research is mainly based on following types of human cells: embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) and mesenchymal stem cells. Main legal and ethical questions concerning the use stem cells are issues affecting creation of human embryos for research purpose only (ESCs), potential oncogenesis (ESCs and iPSCs) and invasive procedures such as bone marrow aspiration or liposuction needed to obtain these cells (MSCs) [15] [16] [17] [18] [19] . Even though mitochondrial-replacement techniques (MRT) already has been used to replace dysfunctional mitochondria in human egg with ones obtained from healthy donors in United Kingdom, many ethics warn it may lead to return of eugenic experiments. Similar questions arise concerning possible injuries and comorbidities of bone marrow and adipose tissue donors. Recently, researchers focus on perinatal tissues like Wharton Jelly and amniotic membrane. Those tissues were proven to contain vast amount of mesenchymal stem cells [2, 20] and comparing with other sources does not evoke ethical issues because typically fetal tissues are disposed as medical waste and MSCs derivation does not require any additional procedures for the patients. Increasing donor age is another factor that negatively affects the immunoregulatory properties of both adipose and bone marrow derived mesenchymal stem cells [21] .
The frequency of MSCs in adipose tissue and bone marrow is about 3% and 0.001% of nucleated cells, respectively. It is not sufficient enough to dream about treating rapidly deteriorating patients [22] [23] [24] . Our data confirms previous findings that fetal tissues can be rich source of autologous MSCs, providing enough material for treatment even within hours from the delivery (with typical doses of 1 mln/kg) and sustainable source for continuing of the therapy.
Fetal MSCs posses higher proliferative potential and less typical signs of senescence at an early stage in comparison to adult ASCs [7] . MSCs derived from Wharton Jelly are known for their ability to modulate immune response and have been successfully used in therapy of acute liver failure [25] and ischemic stroke [9] and lung injury characterized by alveolar damage [26] . In four year observation of patients with refractory systemic lupus erythematosus, no transplantation-related adverse events and the induction of clinical remission and improvement in organ function in drug-resistant SLE patients have been reported [27] .
Recent publications demonstrate that WJ-MSCs has a higher proliferation rate, a greater expansion capability, enhanced neurotrophic factors gene expression and spontaneous tendency toward a neural lineage differentiation when compared with MSCs from bone marrow [3] .
More and more research concentrate on the effect of different culture conditions on the qualities of obtained cells. Lowering oxygen level < 5% was shown to have a beneficial impact on WJ-MSCs. It improved their rate of proliferation, and maintenance of stemness properties during the culture [1] . Such factors like maternal age, the distance of collected umbilical cord fragment from the placenta were also investigated. It was found that WJ-MSCs derived from the extreme cord segments are better source of MSCs compared with cells from the middle segment because of their higher proliferation rate and viability [28] . In the research on 100 term pregnancies, from five maternal age groups (20-45 years), reduced number of cells as well as the level of MSCs markers expression were reported in older mothers [29] .
MSCs show promise for cellular therapy for various diseases associated with inflammation or auto-immunological disorders. Despite fact that fetal MSCs have been shown to be non-tumorogenic [30] , safety rules must be obeyed. MSCs were shown to interact with cancer cells, revoking them from a dormant state in breast cancer [31] . Other scientists consider their activity as antitumor, because despite co-culture with MSCs enhanced survival of nutrient deprived breast cancer cells in vitro, at the same time it suppressed their tumorigenicity which leads for the prevention of cancer recurrence [32] . Recent preclinical studies conducted on animal models prove a presumption that MSCs can be a tool in treating hypoxic-ischemic injury in neonates [33] . It was shown that transplantation of MSCs ameliorate inflammation-induced neuronal cellular degeneration, reduce microgliosis and prevent reactive astrogliosis in rat neonates [34] . Additionally, preclinical research demonstrate that MSCs-based therapies have potential for protecting the developing lung from injury. In expert's opinion the evidence supporting this potential therapeutic role has provided the basis for the initiation of phase I and II clinical trials in preterm neonates [35] . Based on these arguments, further clinical research is needed to ensure patient safety before MSCs application in treatment of premature neonates [36] . The cited research has been performed in animal model and according to authors best knowledge our results are the first confirming the efficacy of human premature MSCs.
CONCLUSION
Human Wharton Jelly and amniotic membrane derived mesenchymal stem cells can be easily obtained and cultured from premature tissues. Presented results suggest that preterm fetal tissues contain MSCs which show similar immunosuppressive capacity as ones from term pregnancies. Premature fetal MSCs from early third-trimester pregnancy have the capacity to inhibit proliferation of allo-activated lymphocytes in an in vitro transplantation model. In the future they may be potentially used to prevent immuno-dependent injuries in premature newborns.
